Michael Schultz
About
Detail
Co-Founder and Chief Science Officer Viewpoint Molecular Targeting, DBA Perspective Therapeutics
Coralville, Iowa, United States
Résumé
Jobs
verified_user
0% verified
Co-Founder and Chief Science Officer Viewpoint Molecular Targeting, DBA Perspective TherapeuticsPerspective TherapeuticsJan 2023 - Current (3 years 4 months)Perspective Therapeutics is a clinical stage radiopharmaceutical company developing the next generation of alpha particle therapeutics for cancer.- Chief Science OfficerViewpoint Molecular Targeting IncAug 2013 - Current (12 years 9 months)Founder and Chief Science Officer of a pharmaceutical company specializing in radiopharmaceutical therapies for cancer. Successful in securing over $35M in NIH/NCI SBIR/STTR funding and capital investment to move lead products into the clinical stage of development.
- Associate ProfessorUniversity of IowaAug 2006 - Current (19 years 9 months)Associate Professor of Radiology, with appointments in Pediatrics, Radiation Oncology, Chemistry, Human Toxicology, and the Free Radical and Radiation Biology Program.
Education
verified_user
0% verified
- Doctor of Philosophy - PhD, Oceanography, Chemical and PhysicalFlorida State University
Publications
verified_user
0% verified
- FN-alkyl triphenylvinylpyridinium conjugated dihydroartemisinin perturbs mitochondrial functions resulting in enhanced caFree Radical Biology and MedicineFeb 2021Dihydroartemisinin (DHA) is an FDA-approved antimalarial drug that has been repurposed for cancer therapy because of its preferential antiproliferative effects on cancer versus normal cells. Mitochondria represent an attractive target for cancer therapy based on their regulatory role in proliferation and cell death. This study investigates whether DHA conjugated to innately fluorescent N-alkyl triphenylvinylpyridinium (TPVP) perturbs mitochondrial functions resulting in a differential toxicity of cancer versus normal cells. TPVP-DHA treatments resulted in a dose-dependent toxicity of human melanoma and pancreatic cancer cells, whereas normal human fibroblasts were resistant to this treatment. TPVP-DHA treatments resulted in a G1-delay of th